Cargando…
Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3516686/ https://www.ncbi.nlm.nih.gov/pubmed/23211971 http://dx.doi.org/10.1038/bjc.2012.497 |
| _version_ | 1782252334307344384 |
|---|---|
| author | Gualberto, A Hixon, M L Karp, D D Li, D Green, S Dolled-Filhart, M Paz-Ares, L G Novello, S Blakely, J Langer, C J Pollak, M N |
| author_facet | Gualberto, A Hixon, M L Karp, D D Li, D Green, S Dolled-Filhart, M Paz-Ares, L G Novello, S Blakely, J Langer, C J Pollak, M N |
| author_sort | Gualberto, A |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-3516686 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2012 |
| publisher | Nature Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-35166862012-12-11 Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab Gualberto, A Hixon, M L Karp, D D Li, D Green, S Dolled-Filhart, M Paz-Ares, L G Novello, S Blakely, J Langer, C J Pollak, M N Br J Cancer Retraction Nature Publishing Group 2012-12-04 2012-12-04 /pmc/articles/PMC3516686/ /pubmed/23211971 http://dx.doi.org/10.1038/bjc.2012.497 Text en Copyright © 2012 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
| spellingShingle | Retraction Gualberto, A Hixon, M L Karp, D D Li, D Green, S Dolled-Filhart, M Paz-Ares, L G Novello, S Blakely, J Langer, C J Pollak, M N Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab |
| title | Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab |
| title_full | Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab |
| title_fullStr | Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab |
| title_full_unstemmed | Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab |
| title_short | Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab |
| title_sort | pre-treatment levels of circulating free igf-1 identify nsclc patients who derive clinical benefit from figitumumab |
| topic | Retraction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3516686/ https://www.ncbi.nlm.nih.gov/pubmed/23211971 http://dx.doi.org/10.1038/bjc.2012.497 |
| work_keys_str_mv | AT gualbertoa pretreatmentlevelsofcirculatingfreeigf1identifynsclcpatientswhoderiveclinicalbenefitfromfigitumumab AT hixonml pretreatmentlevelsofcirculatingfreeigf1identifynsclcpatientswhoderiveclinicalbenefitfromfigitumumab AT karpdd pretreatmentlevelsofcirculatingfreeigf1identifynsclcpatientswhoderiveclinicalbenefitfromfigitumumab AT lid pretreatmentlevelsofcirculatingfreeigf1identifynsclcpatientswhoderiveclinicalbenefitfromfigitumumab AT greens pretreatmentlevelsofcirculatingfreeigf1identifynsclcpatientswhoderiveclinicalbenefitfromfigitumumab AT dolledfilhartm pretreatmentlevelsofcirculatingfreeigf1identifynsclcpatientswhoderiveclinicalbenefitfromfigitumumab AT pazareslg pretreatmentlevelsofcirculatingfreeigf1identifynsclcpatientswhoderiveclinicalbenefitfromfigitumumab AT novellos pretreatmentlevelsofcirculatingfreeigf1identifynsclcpatientswhoderiveclinicalbenefitfromfigitumumab AT blakelyj pretreatmentlevelsofcirculatingfreeigf1identifynsclcpatientswhoderiveclinicalbenefitfromfigitumumab AT langercj pretreatmentlevelsofcirculatingfreeigf1identifynsclcpatientswhoderiveclinicalbenefitfromfigitumumab AT pollakmn pretreatmentlevelsofcirculatingfreeigf1identifynsclcpatientswhoderiveclinicalbenefitfromfigitumumab |